CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 39 enrolled
Drug / intervention
GID SVF-2 +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02726945
NCT02726945N/ACompleted
CompareCT.gov

Use of Autologous Adipose-Derived Stromal Vascular Fraction to Treat Osteoarthritis of the Knee: A Controlled, Randomized, Double-Blinded Trial

GID BIO, Inc.·interventional·Posted Apr 4, 2016·Updated Apr 25, 2025

In Brief

A clinical study evaluating GID SVF-2 and Placebo for Osteoarthritis (OA). Completed, enrolled 39 participants across 3 sites.

Detailed Summary

This is a pivotal study. The study will examine the safety and efficacy of autologous adipose-derived stromal vascular fraction (SVF) cells processed with the GID SVF-2 device for pain, function and stiffness in the knees of osteoarthritic subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis (OA)
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 4, 2016
Enrollment StartApr 1, 2016
Primary CompletionApr 1, 2018
Study CompletionOct 1, 2019
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 10.2 years ago

Interventions

GID SVF-2device

The GID SVF-2 device is a sterile single-use disposable canister used for harvesting, filtering, separating, and concentrating autologous stromal vascular fraction cells from adipose tissue for reintroduction to the same patient during a single surgical procedure for treatment of pain associated with joint osteoarthritis.

Placeboother

Placebo Control